• 6-Thioguanine Suppresses EV71 via BIRC3-Mediated Autophagy I

  2026-04-22

  This study demonstrates that 6-thioguanine (6-TG) potently inhibits Enterovirus 71 (EV71) replication in vitro by downregulating BIRC3-mediated autophagy. The findings provide new mechanistic insight into antiviral strategies for hand, foot, and mouth disease (HFMD), offering a promising direction for therapeutic development.

• Berbamine Hydrochloride: Applied NF-κB Activity Inhibitor Wo

  2026-04-21

  Berbamine hydrochloride enables precision inhibition of NF-κB signaling, empowering researchers to dissect tumorigenic pathways and ferroptosis resistance in cancer models. This guide delivers validated assay protocols, troubleshooting strategies, and actionable insights for maximizing its impact in cancer research.

• Transmission Dynamics of Carbapenemase Genes in CREC, Guangd

  2026-04-21

  This study systematically characterizes carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight teaching hospitals in Guangdong, China, during the COVID-19 pandemic. The findings reveal high multidrug resistance, predominant blaNDM-1 carriage, and efficient horizontal gene transfer, informing both resistance surveillance and experimental model design.

• Programming CAR Macrophages In Situ Using mRNA-LNPs for Soli

  2026-04-20

  This study introduces a macrophage-targeted mRNA lipid nanoparticle system enabling in situ programming of chimeric antigen receptor (CAR) macrophages to enhance cancer immunotherapy, particularly against peritoneal metastases. By systematically evaluating diverse CAR designs, the research uncovers key regulatory mechanisms and demonstrates synergy with PD-1/L1 blockade, offering new insights into overcoming immunosuppressive tumor microenvironments.

• Cefepime (BMY-28142): Applied Workflows in Resistance Modeli

  2026-04-20

  Cefepime (BMY-28142) empowers researchers to model central nervous system infections and unravel adaptive resistance mechanisms in Gram-positive and Gram-negative bacteria. This article translates advanced PKPD findings into actionable workflows, with real-world troubleshooting and comparative insights for high-sensitivity, reproducible research.

• Angiotensin 1/2 (2-7): Benchmarks for Vasoconstrictor Peptid

  2026-04-19

  Angiotensin 1/2 (2-7) is a well-defined peptide fragment used in blood pressure regulation research and mechanistic renin-angiotensin system studies. Its biochemical, physiological, and workflow properties are supported by recent peer-reviewed evidence and high-purity product benchmarks. This article details its biological rationale, action, and integration guidelines for reproducible scientific research.

• PPM-18 for iNOS Inhibition: Workflow, Troubleshooting, and I

  2026-04-18

  Harness the specificity of PPM-18 for advanced inflammation and sepsis models with precise inhibition of inducible nitric oxide synthase. This guide delivers data-driven protocols, troubleshooting strategies, and actionable insights grounded in recent translational research.

• Tiamulin (Thiamutilin): Applied Protocols for Veterinary Ass

  2026-04-17

  Tiamulin (Thiamutilin) uniquely addresses both infectious and inflammatory challenges in veterinary and translational research. This guide distills advanced workflows, troubleshooting, and comparative insights—empowering researchers to maximize assay precision and animal health outcomes.

• Pam3CSK4 as a Precision TLR1/2 Agonist: Beyond Protocols to

  2026-04-16

  Discover how Pam3CSK4, a potent TLR1/2 agonist, empowers advanced immune cell activation studies with mechanistic rigor. This article explores its unique advantages for dissecting macrophage nitric oxide production and modulating Th1 responses, offering scientists deeper guidance beyond standard workflows.

• Optimizing Protein Analysis with a Triple Color Prestained M

  2026-04-15

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) streamlines SDS-PAGE and Western blot workflows with unmatched visual clarity and compatibility, especially for phosphoprotein and fluorescent applications. This article translates recent mechanistic research into actionable protocol enhancements, troubleshooting strategies, and comparative insights for advanced protein analysis.

• V5 Epitope Tag Peptide: Precision in Protein Detection Workf

  2026-04-14

  Unlock robust, high-sensitivity protein tracking with the V5 Epitope Tag Peptide. This guide delivers experimental protocols, advanced imaging use-cases, and troubleshooting strategies—leveraging APExBIO's high-purity GKPIPNPLLGLDST peptide for reproducible results in Western blot, immunoprecipitation, and super-resolution microscopy.

• Azithromycin Workflows: Applied Use-Cases in Infection Model

  2026-04-13

  Azithromycin, a leading macrolide antibiotic, empowers researchers to tackle complex bacterial infection models and resistance profiling with robust, reproducible protocols. Drawing from benchmark studies and APExBIO’s validated reagents, this guide unpacks nuanced workflows, troubleshooting, and cross-domain insights for experimental success.

• Dual-Action Inhibitors Promote p38α Dephosphorylation: New M

  2026-04-12

  The referenced study uncovers how certain kinase inhibitors not only block p38α MAP kinase activity but also actively stimulate its dephosphorylation by phosphatases, revealing a dual-action mechanism. These findings suggest a new strategy for achieving greater selectivity and efficacy in targeting the p38 MAPK signaling pathway, with significant implications for anti-inflammatory and cancer research.

• Mubritinib (TAK 165): Bridging Metabolic and HER2 Cancer Res

  2026-04-12

  This thought-leadership article unpacks the evolving role of Mubritinib (TAK 165) as a selective mitochondrial complex I inhibitor, bridging its mechanistic insights in cell metabolism with strategic experimental guidance for translational researchers. Drawing on the latest peer-reviewed studies and best-practice workflows, it contextualizes Mubritinib's unique positioning relative to HER2-driven cancer research, acute myeloid leukemia, and viral lymphomas, while providing actionable protocol parameters and a critical outlook for the next phase of targeted therapy development.

• Mubritinib (TAK 165): Precision Complex I Inhibition in Canc

  2026-04-11

  Mubritinib (TAK 165) redefines mitochondrial and HER2 pathway research by offering robust, selective inhibition for therapy-resistant AML and PEL models. This article delivers actionable experimental protocols, troubleshooting guidance, and contextualizes recent advances in pH-sensitive drug solubility for translational oncology.

455 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page